S. Hamilton

Publications136
h-index31
Citations12,679
Highly Influential Citations313
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Saver
  • 7,123 Publications • 72,001 Citations
  • G. Albers
  • 759 Publications • 61,609 Citations
  • D. Liebeskind
  • 7,186 Publications • 32,870 Citations
  • S. Starkman
  • 348 Publications • 18,265 Citations
  • Publications
  • Influence
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials
View on Elsevier
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
View on Elsevier
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
TLDR
Endovascular thrombectomy for ischemic stroke 6 to 16 hours after a patient was last known to be well plus standard medical therapy resulted in better functional outcomes than standard medical Therapy alone among patients with proximal middle‐cerebral‐artery or internal‐carotid‐arterY occlusion and a region of tissue that was ischeMIC but not yet infarcted.
View on Wolters Kluwer
Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study.
TLDR
For stroke patients treated 3 to 6 hours after onset, baseline MRI findings can identify subgroups that are likely to benefit from reperfusion therapies and can potentially identify sub groups that are unlikely to benefit or may be harmed.
View on PubMed
Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute…
TLDR
This study found no significant rt-PA benefit on the 90-day efficacy end points in patients treated between 3 and 5 hours in patients with acute ischemic stroke, and does not support the use of intravenous rT-PA for stroke treatment beyond 3 hours.
View on PubMed
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
CONTEXT Tissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Administration. OBJECTIVE To assess the safety profile and to document…
View on PubMed
Collateral Effect of Covid-19 on Stroke Evaluation in the United States
Use of Stroke Imaging during the Covid-19 Pandemic The authors reviewed an imaging database used to determine whether patients with acute stroke were eligible to undergo endovascular thrombectomy. ...
View on PubMed
Prehospital and Emergency Department Delays After Acute Stroke: The Genentech Stroke Presentation Survey
TLDR
This large geographically diverse study strongly suggests that the use of emergency medical services is an important modifiable determinant of delay time for the treatment of acute stroke.
View on Wolters Kluwer
The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study…
TLDR
This study found no significant rtPA benefit on any of the planned efficacy end points at 30 and 90 days in patients treated between 0 and 6 hours after stroke onset, and these results do not support the use of intravenous rTPA for stroke treatment >3 hours after onset.
View on PubMed
Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research
View on Elsevier
...
...